vorinostat has been researched along with Rhabdoid Tumor in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Rhabdoid Tumor: A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data demonstrate that HDAC inhibitor treatment in combination with fenretinide or conventional chemotherapy is a promising tool for the treatment of chemoresistant rhabdoid tumors." | 7.79 | The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. ( Borchert, C; Eveslage, M; Frühwald, M; Görlich, D; Hasselblatt, M; Jung, M; Jürgens, H; Kerl, K; Kool, M; Meisterernst, M; Moreno, N; Ries, D; Unland, R, 2013) |
| "Our data demonstrate that HDAC inhibitor treatment in combination with fenretinide or conventional chemotherapy is a promising tool for the treatment of chemoresistant rhabdoid tumors." | 3.79 | The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. ( Borchert, C; Eveslage, M; Frühwald, M; Görlich, D; Hasselblatt, M; Jung, M; Jürgens, H; Kerl, K; Kool, M; Meisterernst, M; Moreno, N; Ries, D; Unland, R, 2013) |
| " The aim of the study presented here was to analyze the effects of a pharmacological inhibition of EZH2 alone and in combination with other anticancer drugs on RTs cells in vitro." | 1.42 | Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines. ( Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R, 2015) |
| "Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls." | 1.38 | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. ( Battmann, C; Bischof, M; Debus, J; Ehemann, V; Haberkorn, U; Huber, PE; Kulozik, AE; Oertel, S; Perez, RL; Stenzinger, A; Thiemann, M; Weber, KJ; Weichert, W, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kerl, K | 1 |
| Ries, D | 1 |
| Unland, R | 2 |
| Borchert, C | 1 |
| Moreno, N | 1 |
| Hasselblatt, M | 1 |
| Jürgens, H | 1 |
| Kool, M | 2 |
| Görlich, D | 1 |
| Eveslage, M | 1 |
| Jung, M | 1 |
| Meisterernst, M | 1 |
| Frühwald, M | 1 |
| Borchardt, C | 1 |
| Clemens, D | 1 |
| Dirksen, U | 1 |
| Frühwald, MC | 1 |
| Thiemann, M | 1 |
| Oertel, S | 1 |
| Ehemann, V | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Bischof, M | 1 |
| Weber, KJ | 1 |
| Perez, RL | 1 |
| Haberkorn, U | 1 |
| Kulozik, AE | 1 |
| Debus, J | 1 |
| Huber, PE | 1 |
| Battmann, C | 1 |
3 other studies available for vorinostat and Rhabdoid Tumor
| Article | Year |
|---|---|
The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Doxo | 2013 |
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; | 2015 |
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Topics: Animals; Apoptosis; Chemoradiotherapy; Disease Models, Animal; Female; Flow Cytometry; Histone Deace | 2012 |